Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Knut Waterloo

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Neuropsychology|September 22, 2022
Regression-based cognitive change norms applied in biochemically defined predementia Alzheimer's diseaseIngvild Vøllo Eliassen, Bjørn-Eivind Kirsebom, Tormod Fladby, et al.
Applied Neuropsychology. Adult|June 18, 2025
Pathological biomarkers for Alzheimer's disease in cognitively unimpaired individuals are not associated with cognitive decline at two-year follow-upIngvild Vøllo Eliassen, Bjørn-Eivind Kirsebom, Knut Waterloo, et al.
Neurobiology of Aging|June 5, 2024
Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer's diseaseStephanie Lindgård Knudtzon, Kaja Nordengen, Gøril Rolfseng Grøntvedt, et al.
The Clinical Neuropsychologist|August 15, 2022
Regression-based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults aged 49-79 and comparison with published normsJacob Espenes, Ingvild Vøllo Eliassen, Fredrik Öhman, et al.
Brain Communications|October 20, 2022
Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patientsBjørn Eivind Kirsebom, Grit Richter, Kaja Nordengen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 10, 2026
Genotype-phenotype interaction in Alzheimer's disease immune activationStephanie Knudtzon, Bjørn-Eivind Kirsebom, Lene Pålhaugen, et al.
Neurology|May 15, 2025
Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer DiseaseFernando Gonzalez-Ortiz, Bjørn-Eivind Kirsebom, Yara Yakoub, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 29, 2025
Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneityBjørn-Eivind Kirsebom, Fernando Gonzalez-Ortiz, Sinthujah Vigneswaran, et al.
Molecular Neurodegeneration|October 14, 2025
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer's disease genetic pathwaysBjørn-Eivind Kirsebom, Johanna Nilsson, Ellen Vromen, et al.
Journal of Neuroinflammation|December 14, 2023
Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer's diseaseKaja Nordengen, Bjørn-Eivind Kirsebom, Grit Richter, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Neuropsychology|September 22, 2022
Regression-based cognitive change norms applied in biochemically defined predementia Alzheimer's diseaseIngvild Vøllo Eliassen, Bjørn-Eivind Kirsebom, Tormod Fladby, et al.
Applied Neuropsychology. Adult|June 18, 2025
Pathological biomarkers for Alzheimer's disease in cognitively unimpaired individuals are not associated with cognitive decline at two-year follow-upIngvild Vøllo Eliassen, Bjørn-Eivind Kirsebom, Knut Waterloo, et al.
Neurobiology of Aging|June 5, 2024
Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer's diseaseStephanie Lindgård Knudtzon, Kaja Nordengen, Gøril Rolfseng Grøntvedt, et al.
The Clinical Neuropsychologist|August 15, 2022
Regression-based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults aged 49-79 and comparison with published normsJacob Espenes, Ingvild Vøllo Eliassen, Fredrik Öhman, et al.
Brain Communications|October 20, 2022
Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patientsBjørn Eivind Kirsebom, Grit Richter, Kaja Nordengen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 10, 2026
Genotype-phenotype interaction in Alzheimer's disease immune activationStephanie Knudtzon, Bjørn-Eivind Kirsebom, Lene Pålhaugen, et al.
Neurology|May 15, 2025
Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer DiseaseFernando Gonzalez-Ortiz, Bjørn-Eivind Kirsebom, Yara Yakoub, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 29, 2025
Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneityBjørn-Eivind Kirsebom, Fernando Gonzalez-Ortiz, Sinthujah Vigneswaran, et al.
Molecular Neurodegeneration|October 14, 2025
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer's disease genetic pathwaysBjørn-Eivind Kirsebom, Johanna Nilsson, Ellen Vromen, et al.
Journal of Neuroinflammation|December 14, 2023
Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer's diseaseKaja Nordengen, Bjørn-Eivind Kirsebom, Grit Richter, et al.
Pageof 9